PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D 21 NOV 2005
WIPO PCT

Applicant's or agent's file reference 728439	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/SG2004/000307	International filing date *(day/month/year)* 21 September 2004	Priority date *(day/month/year)* 22 September 2003
International Patent Classification (IPC) or national classification and IPC Int. Cl. [7] C07D 235/06, 235/26; A61K 31/4184		
Applicant S*BIO PTE LTD et al		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. [X] *(sent to the applicant and to the International Bureau)* a total of **8** sheets, as follows:
      - [X] sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      - [ ] sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.

   b. [ ] *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or table related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

[X]	Box No. I	Basis of the report
[ ]	Box No. II	Priority
[ ]	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
[ ]	Box No. IV	Lack of unity of invention
[X]	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
[ ]	Box No. VI	Certain documents cited
[ ]	Box No. VII	Certain defects in the international application
[ ]	Box No. VIII	Certain observations on the international application

Date of submission of the demand	Date of completion of the report
18 July 2005	3 November 2005
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer **GEORGE D. HEARDER** Telephone No. (02) 6283 2553

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SG2004/000307

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:

☐ international search (under Rules 12.3 and 23.1 (b))

☐ publication of the international application (under Rule 12.4)

☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the **elements** of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):

☐ the international application as originally filed/furnished

☒ the description:

pages **1-5, 7-9, 11-13, 15-26, 28-110** as originally filed/furnished
pages* **6, 10, 14, 27** received by this Authority on **18 July 2005** with the letter of 14 July 2005
pages* received by this Authority on with the letter of

☒ the claims:

pages **111-113, 116-122, 125-136** as originally filed/furnished
pages* as amended (together with any statement) under Article 19
pages* **114, 115** received by this Authority on **18 July 2005** with the letter of 14 July 2005
pages* **123, 124** received by this Authority on **27 October 2005** with the letter of **25 October 2005**

☐ the drawings:

pages as originally filed/furnished
pages* received by this Authority on with the letter of
pages* received by this Authority on with the letter of

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages
☐ the claims, Nos.
☐ the drawings, sheets/figs
☐ the sequence listing (*specify*):
☐ any table(s) related to the sequence listing (*specify*):

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages
☐ the claims, Nos.
☐ the drawings, sheets/figs
☐ the sequence listing (*specify*):
☐ any table(s) related to the sequence listing (*specify*):

* *If item 4 applies, some or all of those sheets may be marked "superseded."*

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SG2004/000307

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1: Statement

Novelty (N)	Claims	1-42	YES
	Claims		NO
Inventive step (IS)	Claims	1-42	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-42	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1 CA 136:131135
D2 WO 2000/042022
D3 WO 2003/077855
D4 WO 2003/077914
D5 WO 2003/087089
D6 WO 2003/000682
D7 WO 2003/000254
D8 WO 2002/050062
D9 WO 2001/047883
D10 WO 2001/005390
D11 WO 2001/012604
D12 WO 2001/005393
D13 WO 2001/000207
D14 WO 2001/000213

Please refer to the International Search Report for a full listing of the cited documents and their classification with regard their relevance to the claims searched.

Novelty (N)

The present invention relates to benzimidazole compounds substituted with hydroxamate derivatives via a linker. None of the listed prior art documents discloses the use of linkers, all the disclosed compounds having the hydroxamate moiety directly bound to the benzimidazole.
Therefore the subject matter of these claims is new and meets the requirements of Article 33(2) PCT with regard to novelty.

Inventive Step (IS)

The claimed invention is not obvious in the light of any of the cited documents nor is it disclosed in any obvious combination of them. It is also considered that it would not be obvious to a person skilled in the art in the light of common general knowledge either by itself or in combination with any of these documents.

Industrial Applicability (IA)

The invention defined in the claims is considered to meet the requirements of Industrial Applicability under Article 33(4) of the PCT.

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

d) $L=L^1-W-L^2$

L^1 and L^2 are the same or different and independently selected from C_1–C_5 alkyl, which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; $-NO_2$; $-CF_3$, $-OCF_3$, alkyl, alkoxy, acylamino, alkylamino;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

R^9 and R^{10} are the same or different and are independently selected from H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; and acyl;

Z is selected from $-CH_2-$, $-CH_2CH_2-$, -CH=CH- and C_3-C_6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl; or a pharmaceutically acceptable salt thereof.

One suitable genus of hydroxamic compounds are those of formula Ia:



Formula Ia

wherein

R^1 is selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, arylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR^6 and acyl, each of which may be unsubstituted or

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

d) $L=L^1-W-L^2$

L^1 and L^2 are the same or different and independently selected from C_1-C_5 alkyl, which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; $-NO_2$; $-CF_3$, $-OCF_3$, alkyl, alkoxy, acylamino, alkylamino;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

R^9 and R^{10} are the same or different and are independently selected from H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; and acyl;

Z is selected from $-CH_2-$, $-CH_2CH_2-$,-CH=CH-, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

Another group of useful compounds are those of the formula Ib:



Formula Ib

wherein

R^1 is selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, arylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR^6 and acyl, each of which may be unsubstituted or

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

d) $L=L^1-W-L^2$

L^1 and L^2 are the same or different and independently selected from C_1-C_5 alkyl, which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; $-NO_2$; $-CF_3$, $-OCF_3$, alkyl, alkoxy, acylamino, alkylamino;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, $-SO_2N(R^9)-$, $N(R^9)C(O)-$, $N(R^9)SO_2-$, and $-N(R^9)-C(O)-N(R^{10})-$;

R^9 and R^{10} are the same or different and are independently selected from H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; and acyl;

Z is selected from $-CH_2-$, $-CH_2CH_2-$,-CH=CH-, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

As with any group of structurally related compounds which possess a particular utility, certain groups are preferred for the compounds of the Formula (I), (Ia) and (Ib) in their end use application.

In certain preferred embodiments R^1 is selected from the group consisting of C_1-C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4-C_9 heterocycloalkylalkyl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl each of which may be substituted as previously stated.

In another embodiment it is preferred that R^1 is selected from the group consisting of H, hydroxyalkyl, alkyl, arylalkyl, heteroarylalkyl, alkoxyalkyl, aminoalkyl, and heterocycloalkyl each of which may be substituted as previously stated.

In another embodiment it is preferred that R^1 is selected from the group consisting of H, hydroxyalkyl, alkyl, alkoxyalkyl, and aminoalkyl each of which may be substituted as previously stated.

c) L=Cy-(CH_2)m-W-

Wherein,

Cy is C_1-C_{15} alkyl, aminoalkyl, heterocycloalkyl, cycloalkyl, aryl, aryloxy or heteroaryl, any of which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen, =O, =S, -CN, $-NO_2$, $-CF_3$, $-OCF_3$, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, -COOH, $C(O)OR^6$, $-COR^5$, -SH, $-SR^6$, $-OR^6$and acyl;

m is 0, 1, 2, 3, 4 or 5;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2$-, $-N(R^9)$-, $-C(O)N(R^9)$-, $-SO_2N(R^9)$-, $N(R^9)C(O)$-, $N(R^9)SO_2$-, and $-N(R^9)$-C(O)-$N(R^{10})$-;

d) L=L^1-W-L^2

L^1 and L^2 are the same or different and independently selected from C_1–C_5 alkyl, which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; $-NO_2$; $-CF_3$, $-OCF_3$, alkyl, alkoxy, acylamino, alkylamino;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2$-, $-N(R^9)$-, $-C(O)N(R^9)$-, $-SO_2N(R^9)$-, $N(R^9)C(O)$-, $N(R^9)SO_2$-, and $-N(R^9)$-C(O)-$N(R^{10})$-;

R^9 and R^{10} are the same or different and are independently selected from H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; and acyl;

Z is selected from $-CH_2$-, $-CH_2CH_2$-,-CH=CH-, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2$-, $-N(R^9)$-, $-C(O)N(R^9)$-, $-SO_2N(R^9)$-, $N(R^9)C(O)$-, $N(R^9)SO_2$-, and $-N(R^9)-C(O)-N(R^{10})$-;

c) $L=Cy-(CH_2)m-W-$

Wherein,

Cy is C_1-C_{15} alkyl, aminoalkyl, heterocycloalkyl, cycloalkyl, aryl, aryloxy or heteroaryl any of which may be optionally substituted one or more substituents independently selected from the group consisting of: : halogen, =O, =S, -CN, $-NO_2$, $-CF_3$, $-OCF_3$, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, -COOH, $C(O)OR^5$, $-COR^5$, -SH, $-SR^5$, $-OR^6$and acyl;

m is 0, 1, 2, 3, 4 or 5;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2$-, $-N(R^9)$-, $-C(O)N(R^9)$-, $-SO_2N(R^9)$-, $N(R^9)C(O)$-, $N(R^9)SO_2$-, and $-N(R^9)-C(O)-N(R^{10})$-;

d) $L=L^1-W-L^2$

L^1 and L^2 are the same or different and independently selected fromC_1–C_5 alkyl, which may be optionally substituted one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; $-NO_2$; $-CF_3$, $-OCF_3$, alkyl, alkoxy, acylamino, alkylamino;

W is selected from the group consisting of a single bond, -O-, -S-, -S(O)-, $-S(O)_2$-, $-N(R^9)$-, $-C(O)N(R^9)$-, $-SO_2N(R^9)$-, $N(R^9)C(O)$-, $N(R^9)SO_2$-, and $-N(R^9)-C(O)-N(R^{10})$-;

R^9 and R^{10} are the same or different and are independently selected from H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; and acyl;

Z is selected from $-CH_2$-, $-CH_2CH_2$-, -CH=CH-, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein Z is $-CH_2-$, $-CH_2CH_2-$, or -CH=CH-, C_3-C_6 cycloalkyl, and Z is attached at ring position 5 or 6.

3. A compound of claim 1 or 2 wherein Z is -CH=CH-, and is attached at ring position 5.

4. A compound of any one of claims 1 to 3 wherein R^3 = H.

5. A compound of any one of claims 1 to 4 wherein X and Y = H.

6. A compound according to any one of claims 1 to 5 wherein R^4 = H.

7. The compound according to any one of claims 1 to 6 wherein R^1 is selected from the group consisting of: H, hydroxyalkyl, alkyl, arylalkyl, heteroarylalkyl, alkoxyalkyl, aminoalkyl, and heterocycloalkyl, each of which may be unsubstituted or substituted.

8. The compound according to any one of claims 1 to 7 wherein R^1 is selected from the group consisting of: H; methyl; (pyridin-2-yl)methyl; (pyridin-3-yl)methyl; ethyl; 2-hydroxy-ethyl; 2-(pyridin-2-yl)ethyl; 2-(pyridin-3-yl)ethyl; 2-phenyl-ethyl; 2-carboxy-ethyl; 2-(morpholin-4-yl)-ethyl; 2-(piperidin-1-yl)-ethyl; 2-(pyrollidin-1-yl)-ethyl; 2-diethylamino-ethyl; propyl; 2,3-di-hydroxy-propyl; 3-hydroxy-propyl; 3-methoxy-propyl; 3-isopropoxy-propyl; 2,2-dimethyl-propyl; 3-dimethylamino-propyl; 3-dimethylamino-2,2-dimethyl-propyl; 3-(2-oxo-pyrollidin-1-yl)-propyl; 3-(morpholin-4-yl)-propyl; 3-(imadazol-1-yl)-propyl; 3-(4-methyl-piperidin-1-yl)-propyl; 3-(pyrollidin-1-yl)-propyl; 4-dimethylamino-butyl; 5-hydroxy-pentyl; allyl; benzyl; 3,4,5-trimethoxybenzyl.

9. A compound according to any one of claims 1 to 8 wherein R^2 is selected from the group consisting of H, alkyl, arylalkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, each of which may be unsubstituted or substituted.

10. A compound according to any one of claims 1 to 9 wherein R^2 is,: H; methyl; benzylamino-methyl; dibenzylamino-methyl; [2-(4-fluoro-phenyl)-acetylamino]-methyl; [2-(4-methoxy-phenyl)-acetylamino]-methyl; 4-methoxy-benzylamino-methyl; benzyloxy-methyl; phenylacetylamino-methyl; 1-amino-2-phenyl-ethyl; 2-benzylamino-ethyl; 2-(3-methoxy-phenyl)-ethyl; 2-(pyridin-3-yl)ethyl; 2-(2-phenoxyacetylamino)-ethyl; 2-benzenesulphonylamino-ethyl; 2-phenyl-ethyl; isopropyl; 2-phenyl-propyl; 3-phenyl-propyl; 3-phenoxy-propyl; 3-(1H-indol-3-yl)-propyl; 4-methoxy-phenyl; 4-fluoro-phenyl; 4-



N-Hydroxy-3-(1-Ethyl-1*H*-benzimidazol-5-yl}-acrylamide



N-Hydroxy-3-[2-(2-phenyl-propyl)-1-(2-pyridin-3-yl-ethyl)-1*H*-benzimidazol-5-yl]-acrylamide



N-Hydroxy-3-[1-(2-pyridin-2-yl-ethyl)-1*H*-benzimidazol-5-yl]-acrylamide



N-Hydroxy-3-(1-Ethyl-2-methyl-1*H*-benzimidazol-5-yl]-acrylamide



N-Hydroxy-3-[1-(2-morpholin-4-yl-ethyl)-2-phenethyl-1*H*-benzimidazol-5-yl]-acrylamide



N-Hydroxy-3-[2-phenethyl-1-(3,4,5-trimethoxy-benzyl)-1*H*-benzimidazol-5-yl]-propionamide



N-hydroxy-3-[1-(3-hydroxy-propyl)-2-isopropyl-1*H*-bezimidazol-5-yl]-acrylamide



N-Hydroxy-3-(1-methyl-2-phenethyl-1*H*-benzimidazol-5-yl)-acrylamide



N-Hydroxy-3-(1-methyl-1*H*-benzimidazol-5-yl)-acrylamide



N-Hydroxy-3-(2-phenethyl-1*H*-benzimidazol-5-yl)-acrylamide



N-Hydroxy-3-(1*H*-benzimidazol-5-yl)-acrylamide